Infliximab as a Second-Line Therapy for Children with Refractory Kawasaki Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Suad Kabbaha, Alyssa Milano, Mamoon A Aldeyab, Kristian Thorlund

Research output: Contribution to journalReview articlepeer-review

Fingerprint

Dive into the research topics of 'Infliximab as a Second-Line Therapy for Children with Refractory Kawasaki Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials'. Together they form a unique fingerprint.

Medicine & Life Sciences